Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial | MicrobiomeTrials← Back to trialsNCT06593431
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2024-10-23Est. Completion: 2029-06-29
Enrollment target: 80 participants Locations- Cooper Hospital University Medical Center, Camden, New Jersey, United States
- Cooper Hospital University Medical Center, Voorhees Township, New Jersey, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Post-Hepatectomy Liver FailureLiver FailureLiver NeoplasmsCarcinoma, HepatocellularLiver MetastasesPostoperative ComplicationsHepatic Congestion
Removing a large part of the liver (major hepatectomy) can cure primary and secondary liver cancers, but it carries the …
Minya, EgyptEst. completion Apr 30, 2028
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor
Urinary Bladder Neoplasm
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
Esophageal Cancer
Pancreatic Cancer
Ovarian Cancer
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Renal Pelvis Cancer
Bladder Cancer
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in particip…
Duarte, United StatesEst. completion May 2027